Author Interviews, Duke, Leukemia, Nature / 12.12.2025

MedicalResearch.com Interview with: [caption id="attachment_71759" align="alignleft" width="200"]Dr. Hirschey Dr. Matthew Hirschey[/caption] Matthew Hirschey Ph.D. Associate Professor of Medicine Associate Professor of Cell Biology Associate Professor in Pharmacology and Cancer Biology Member of the Duke Cancer Institute Member of Sarah W. Stedman Nutrition and Metabolism Center Hirschey Lab in the Duke Molecular Physiology Institute, Duke University MedicalResearch.com: What is the background for this study? Would you briefly describe AML and why new therapeutic approaches are needed? Response: Acute myeloid leukemia (AML) is an aggressive blood cancer that begins in the bone marrow and progresses rapidly. While recent advances, particularly the BCL-2 inhibitor venetoclax combined with other agents, have improved outcomes for some patients, many still relapse or don't respond to treatment. The five-year survival rate remains below 30% overall, highlighting an urgent need for new therapeutic strategies. We know that cancer cells rewire their metabolism to fuel rapid growth, and the mitochondria (the cell's powerhouses) play a central role. However, understanding exactly how different metabolic pathways connect and depend on each other has been challenging. We wanted to develop better tools to map these connections and identify new vulnerabilities we could potentially target.
Author Interviews, Gastrointestinal Disease, Genetic Research, Hepatitis - Liver Disease / 25.04.2025

MedicalResearch.com Interview with: [caption id="attachment_68138" align="alignleft" width="125"]Ashley Jowell, MD, Internal Medicine Resident Physician Duke University  Dr. Jowell[/caption] Ashley Jowell, MD, Internal Medicine Resident Physician Duke University   [caption id="attachment_68139" align="alignleft" width="125"]Cynthia Moylan, MDAssociate Professor of Medicine, Division of Gastroenterology Duke University Health System Dr. Moyland[/caption] Cynthia Moylan, MD Associate Professor of Medicine, Division of Gastroenterology Duke University Health System       MedicalResearch.com: What is the background for this study? Response: Metabolic dysfunction can lead to several health problems including metabolic dysfunction associated steatotic liver disease (MASLD), is driven by different factors, including: a person’s behavioral or lifestyle factors, environmental factors, and genetics. Limited research exists regarding genetic , epigenetic, or other factors that might impact development of metabolic dysfunction and MASLD. Our group has previously shown that alterations in DNA methylation (a type of epigenetic change), identifiable both in liver tissue and in blood, associate with MASLD and its progression to more severe liver disease.  Whether DNA methylation that impacts imprinted gene expression also associates with metabolic dysfunction and MASLD risk remains largely unknown. In this project, we explored imprinted genes: imprinting is a normal process that regulates genes by silencing one parental copy (either the maternal or the paternal) so that only one copy is expressed. Imprinting is an important biological process for development and has a disproportionate impact on disease  - in fact, imprinted genes are hypothesized to affect 1-6% of the human genome. We sought to explore how altered DNA methylation of imprint control regions (ICRs) that help ‘control’ these imprinted genes might impact development of metabolic dysfunction in children (and hence potentially even in adults).
Author Interviews, JAMA, Kidney Disease, Medicare / 10.04.2020

MedicalResearch.com Interview with: Lead and Senior coauthors contributing to this interview: [caption id="attachment_53849" align="alignleft" width="105"] Abby Hoffman[/caption] Abby Hoffman, BA is a Pre-Doctoral Fellow in Population Health Sciences at Duke University and a PhD Candidate in Health Policy and Management University of North Carolina at Chapel Hill. [caption id="attachment_53850" align="alignleft" width="117"]Virginia Wang, PhD, MSPH is an Associate Professor in the Department of Population Health Sciences, Associate Director of the Center for Health Innovation and Outcomes Research, and Core Faculty at the Margolis Center for Health Policy at Duke University and Investigator at Durham VA HSR&D Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT). Dr. Virginia Wang[/caption] Virginia Wang, PhD, MSPH is an Associate Professor in the Department of Population Health Sciences, Associate Director of the Center for Health Innovation and Outcomes Research, and Core Faculty in the Margolis Center for Health Policy at Duke University and Investigator at the Durham VA HSR&D Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT).   MedicalResearch.com: What is the background for this study? Response: It is well established that healthcare providers are sensitive to changes in price, though their behavioral response varies. Dialysis facilities are particularly responsive to changes in Medicare reimbursement. Many dialysis patients are eligible for Medicare regardless of age, but dialysis facilities generally receive significantly higher reimbursement from private insurers than from Medicare. In 2011, Medicare implemented a new prospective bundled payment for dialysis that was expected to decrease Medicare payment and reduce overall revenues flowing into facilities. Then the Affordable Care Act (ACA) rules against refusing to insure patients for preexisting conditions and the 2014 ACA Marketplace provided an additional avenue for patients to purchase private insurance. As a result of these policies, dialysis facilities had a strong motivation and opportunity to increase the share of patients with private insurance coverage. We were interested in understanding whether dialysis facilities were shifting their payer mix away from Medicare, possibly in response to these policy changes. 
Aging, Author Interviews, Circadian Rhythm / 21.03.2019

MedicalResearch.com Interview with: [caption id="attachment_48030" align="alignleft" width="200"]Adrian Bejan PhD ( MIT 1971, 1972, 1975 )J.A. Jones Distinguished Professor Duke University Dr. Bejan[/caption] Adrian Bejan PhD ( MIT 1971, 1972, 1975 ) J.A. Jones Distinguished Professor Duke University MedicalResearch.com: What is the background for this study? What are the main findings? Response: Among the most common human perceptions is that time passes faster as an individual becomes older. The days become shorter, and so do the years. We all have stories of this kind, from the long days of childhood and the never-ending class hours in elementary school, to days, months and years that now pass in a blur. Why does it feel that the time passes faster as we get older? What is the physical basis for the impression that some days are slower than others? Why do we tend to focus on the unusual (the surprise), not on the ever present? This new article unveils the physics basis for these common observations. The reason is that the measurable ‘clock time’ is not the same as the time perceived by the human mind. The ‘mind time’ is a sequence of images, i.e. reflections of nature that are fed by stimuli from sensory organs. The rate at which changes in mental images are perceived decreases with age, because of several physical features that change with age: saccades frequency, body size, pathways degradation, etc. The misalignment between mental-image time and clock time serves to unite the voluminous observations of this phenomenon in the literature with the constructal law of evolution everywhere, as physics.